多药耐药基因蛋白P-gp和ABCG2在喉癌等头颈肿瘤中的作用及相关信号通路

doi:10.6040/j.issn.1673-3770.0.2015.469

摘要/Abstract

摘要： 喉癌作为恶性实体肿瘤,化学药物疗法在其综合治疗中扮演着日益重要的角色,但多药耐药(MDR)的产生成为导致化疗失败的主要原因。研究表明,多药耐药基因蛋白P-gp和ABCG2在喉癌的MDR中起着重要作用,P-gp和ABCG2之间或正或负呈相关性,其相关信号通路(MAPK)与P-gp和ABCG2在肿瘤中的表达也有一定的相关性,但其调控因素及如何由此提高化疗效果有待进一步研究。

关键词: ABCG2, P-gp, 多药耐药, 喉肿瘤

Abstract: Laryngocatcinoma is a type of malignant solid tumor, and chemotherapy plays an increasingly important role in its treatment, but multidrug resistance(MDR)has become the leading cause of chemotherapy failure. Researches have showed that P-gp and ABCG2 proteins are important in the MDR of laryngocatcinoma, P-gp may be positively or negatively correlated with ABCG2, and their related signal pathways(MAPK)are related to their expressions in tumors. However, how P-gp and ABCG2 are controlled and how to improve the effect of chemotherapy remain to be further investigated.

Key words: ABCG2, Multidrug resistance, Laryngeal cancer, P-gp

中图分类号:

R739.65

苏甜甜,张佳综述,孙臻峰审校. 多药耐药基因蛋白P-gp和ABCG2在喉癌等头颈肿瘤中的作用及相关信号通路[J]. 山东大学耳鼻喉眼学报, 2016, 30(3): 103-106.

SU Tiantian, ZHANG Jia, SUN Zhenfeng. Roles of multidrug resistance proteins P-gp and ABCG2 in laryngocatcinoma and their related signal pathways.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 103-106.

参考文献

[1] Wang X B, Wang S S, Zhang Q F, et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells[J]. Oncol Rep, 2010, 23(1):211-215.
[2] Biedler J L, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies[J]. Cancer Res, 1970, 30(4):1174-1184.
[3] Juliano R L, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta,1976, 455(1):152-162.
[4] 李圆, 吴正虎, 周雪华, 等. 四种耐药基因蛋白在喉癌组织中的表达及临床意义[J]. 浙江医学, 2010, 32(9):1333-1335. LI Yuan, WU Zhenghu, ZHOU Xuehua, et al. Expression of multidrug resistance proteins in laryngocatcinoma and its clinical significance[J]. Zhejiang Med J, 2010, 32(9):1333-1335.
[5] 杨征, 黄志刚, 钟琦, 等. 喉癌中p53与MDR1及MRP表达的相关性研究[J]. 中国耳鼻咽喉头颈外科, 2008, 15(5):289-292. YANG Zheng, HUANG Zhigang, ZHONG Qi, et al. Relationship between expression of p53 and MDRl, MRP in laryngeal cancer[J]. Chin Otolaryngol Otolaryngol Head Neck Surg, 2008, 15(5):289-292.
[6] Li L, Jiang A C, Dong P, et al. The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol[J]. Otolaryngol Head Neck Surg, 2007, 137(4):659-664.
[7] Li L, Jiang A C, Dong P, et al. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol[J]. Ann Surg Oncol, 2009, 16(5):1421-1428.
[8] Chen J S, Pardo F S, Wang-Rodriguez J, et al. EGFR regulates the side population in head and neck squamous cell carcinoma[J]. Laryngoscope, 2006, 116(3):401-406.
[9] Lopez J P, Wang-Rodriguez J, Chang C, et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines[J]. Arch Otolaryngol Head Neck Surg, 2007, 133(10):1022-1027.
[10] Tsunoda S, Okumura T, Ito T, et al. ABCG2 expression is an independent unfavorable prognostic factor in Esophageal squamous cell carcinoma[J]. Oncology-Basel, 2006, 71(3-4):251-258.
[11] Wang J, Guo L P, Chen L Z, et al. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line[J]. Cancer Res, 2007, 67(8):3716-3724.
[12] Chu T S, Chen J S, Lopez J P, et al. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma[J]. Arch Otolaryngol Head Neck Surg, 2008, 134(9):979-984.
[13] 沈斌, 董频. 乳腺癌耐药蛋白结构、功能及其在人体肿瘤中作用的研究进展[J]. 山东大学耳鼻喉眼学报, 2011, 25(3): 28-33. SHEN Bin, DONG Pin. Advances in breast cancer resistance protein structure, function and its role in human tumors[J]. J Otolaryngol Ophthalmol Shandong Univ, 2011, 25(3): 28-33.
[14] 沈斌, 董频, 英信江, 等. ABCG2及NF-κB p65在下咽癌中的表达意义[J]. 山东大学耳鼻喉眼学报, 2012, 26(4):17-20. SHEN Bin, DONG Pin, YING Xinjiang, et al. Expressions and implication of ABCG2 and NF-κB p65 in hypopharyngeal cancer[J]. J Otolaryngol Ophthalmol Shandong Univ, 2012, 26(4):17-20.
[15] Krishnamurthy P, Schuetz J D. Role of ABCG2 BCRP in biology and medicine[J]. Arm Rev Pharmacol Toxicol, 2006, 46(2):381-410.
[16] 史博. 胰腺癌中ABCG2和P-gp的表达及意义[D]. 中国医科大学, 2010.
[17] Cisternino S, Mercier C, Bourasset F, et al. Expression, up-regulation and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier[J]. Cancer Res, 2004, 64(9):3296-3301.
[18] Stein U, Walther W, Lemm M, et al. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo[J]. Int J Cancer, 1997, 72:885-891.
[19] Bark H, Xu H D, Kim S H, et al. P-glycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state[J]. FEBS Letters, 2008, 582(17): 2595-2600.
[20] Poller B, Drewe S, Krahenbuhl S, et al. Regulation of BCRP(ABCG2)and P-glycoprotein(ABCB1)by cytokines in a model of the human blood-brain barrier[J]. Cell Mol Neurobiol, 2010, 30(1):63-70.
[21] Trock B J, Leonessa F, Clarke R. Multidrug resistance and breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance[J]. J Natl Cancer Inst, 1997, 89(13):917-931.
[22] 孙臻峰, 沈斌, 苏甜甜, 等. 耐药基因MDR1(P-gp)和ABCG2在Hep-2细胞耐药中的作用研究[J]. 临床耳鼻咽喉头颈外科杂志, 2015, 29(11):1016-1020. SUN Zhenfeng, SHEN Bin, SU Tiantian, et al. The study of the interaction of MDR1(P-gp)and ABCG2 in Hep 2 cells[J]. Clin J Otorhinolarynol Head Neck Surg, 2015, 29(11):1016-1020.
[23] Carpenter G, Cohen S. Epidermal growth factor[J]. Annu Rev Biochem, 1979, 48(7):193-216.
[24] Shi Z, Peng X X, Kim I W, et al. Erlotinib(Tarceva, OSI-774)antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance[J]. Cancer Res, 2007, 67(22):11012-11020.
[25] Dai C L, Tiwari A K, Wu C P, et al. Lapatinib(Tykerb, GW572016)reverses multidrug resistance in cancer cells by inhibiting the activity of ATP binding cassette subfamily B member 1 and G member 2[J]. Cancer Res, 2008, 68(19):7905-7914.
[26] Graber-Maier A, Gutmann H, Drewe J. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib[J]. Mol Pharm, 2010, 7:1618-1628.

相关文章 15

[1]	付玉贵,王海兰,孙德重,杨佩珍,陈彦林,陈志鹏. 保留部分环状软骨环的喉全切除术[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 73-75.
[2]	张明德,张祖平,于学民,魏燕红,袁英. RASSF2A基因甲基化在喉癌组织中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 64-67.
[3]	马玲国,郑朝攀,周敬淳,张博,龚桃根,张云静. CO₂激光治疗声门型喉癌远期疗效分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 98-100.
[4]	王守玺, 刘荷珍. 声门上水平喉部分切除术中舌骨去留对误咽的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(4): 45-47.
[5]	严羽, 朱江. 早期喉癌及喉癌前病变诊断的研究进展[J]. 山东大学耳鼻喉眼学报, 2015, 29(4): 80-85.
[6]	陈小玲, 费兵, 李贤斌, 吴昊. 靶向人喉癌HEP2细胞Trop2基因的siRNA构建及鉴定[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 51-53.
[7]	王玉红, 王倩, 陈萍, 钱晓云. 原发于喉部的非鳞状细胞癌11例并文献复习[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 83-88.
[8]	刘荷珍. 甲状软骨外膜和胸骨舌骨肌用于声门型喉癌切除喉重建临床分析[J]. 山东大学耳鼻喉眼学报, 2014, 28(4): 49-51.
[9]	田俊, 王丹丹, 皇甫辉, 王斌全, 李乐. 喉癌CT/MRI融合图像的建立及初步应用[J]. 山东大学耳鼻喉眼学报, 2014, 28(4): 52-55.
[10]	王英俊，孙彦，李薇，华辉，黄沂传，葛瑞锋，韩敏. 喉癌、喉咽癌手术相关肺血栓栓塞症的临床特点[J]. 山东大学耳鼻喉眼学报, 2014, 28(2): 51-54.
[11]	魏希建1，阴瑞兰2，郭星3. 增殖诱导配体在喉鳞状细胞癌中的表达[J]. 山东大学耳鼻喉眼学报, 2014, 28(1): 14-16.
[12]	刘昉1，赖建新1，李瑞玉1，李冠桢2. 喉癌患者外周血中Th17/Treg比率变化[J]. 山东大学耳鼻喉眼学报, 2013, 27(5): 4-7.
[13]	王晓彬1,潘新良2,卢永田1,魏明辉1,孙焕吉1，苗北平1. 早期声门区癌的手术治疗及疗效评估[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 53-58.
[14]	郭红光，李进让，孙建军. CO2激光声带切除术后复发相关因素分析[J]. 山东大学耳鼻喉眼学报, 2013, 27(1): 54-57.
[15]	卢国伟，王琳，孙彦，李薇，华辉，葛瑞峰. 山东东部57例喉癌人乳头状瘤病毒DNA及其亚型的检测[J]. 山东大学耳鼻喉眼学报, 2012, 26(6): 16-19.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed